These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6677708)

  • 1. [Interdependence between hormonal disorders, stage of development and degree of malignancy of prostatic cancer. 1].
    Szymanowski J; Baranowska B; Niewiadomska A; Wysocki M; Kobuszewska-Faryna M; Zgliczynski S
    J Urol (Paris); 1983; 89(8):597-600. PubMed ID: 6677708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interdependence between hormonal disorders, staging and degree of malignancy of prostatic gland cancer. 2].
    Szymanowski J; Baranowska B; Rozbicka G; Jeske W; Zgliczynski S
    J Urol (Paris); 1983; 89(9):663-8. PubMed ID: 6425418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer.
    Hsing AW; Comstock GW
    Cancer Epidemiol Biomarkers Prev; 1993; 2(1):27-32. PubMed ID: 8420607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hormonal disturbances in men with a prostatic adenoma (author's transl)].
    Baranowska B; Zgliczynski S; Szymanowski J
    J Urol (Paris); 1980; 86(7):551-8. PubMed ID: 6161196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade prostate cancer is associated with low serum testosterone levels.
    Schatzl G; Madersbacher S; Thurridl T; Waldmüller J; Kramer G; Haitel A; Marberger M
    Prostate; 2001 Apr; 47(1):52-8. PubMed ID: 11304729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
    Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
    Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and late long-term effects of vasectomy on serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone levels.
    Mo ZN; Huang X; Zhang SC; Yang JR
    J Urol; 1995 Dec; 154(6):2065-9. PubMed ID: 7500459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?
    Imamoto T; Suzuki H; Yano M; Kawamura K; Kamiya N; Araki K; Komiya A; Naya Y; Shiraishi T; Ichikawa T
    Prostate Cancer Prostatic Dis; 2009; 12(1):78-82. PubMed ID: 18521100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormone determinations in andrology].
    Frick J
    Andrologia; 1980; 12(3):211-8. PubMed ID: 6778255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum androgens: associations with prostate cancer risk and hair patterning.
    Demark-Wahnefried W; Lesko SM; Conaway MR; Robertson CN; Clark RV; Lobaugh B; Mathias BJ; Strigo TS; Paulson DF
    J Androl; 1997; 18(5):495-500. PubMed ID: 9349747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
    Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal status in prostatic disease.
    Frick J; Bartsch G
    Prog Clin Biol Res; 1976; 6():143-58. PubMed ID: 66687
    [No Abstract]   [Full Text] [Related]  

  • 17. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Suzuki K; Takahashi K
    J Urol; 2006 Oct; 176(4 Pt 1):1387-91. PubMed ID: 16952639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
    Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
    Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.